• Eric P. Bastings
  • Amelito Malapira
Part of the Current Clinical Neurology book series (CCNEU)


In spastic patients, suprasegmental lesions interfere with descending control of interneuronal systems in the spinal cord. A better understanding of neurotransmitters and neuromodulators active in these interneuronal circuits has been the basis for pharmacological manipulation of spasticity (see Chapter 2 for further details). One of the most powerful drugs and certainly the most widely used in the past 30 years has been baclofen. Baclofen (4-amino-3-[p-chlorophenyl]-GABA) was initially developed as an antiepileptic medication. It did not prove to be very effective in this indication, and later studies actually suggested a possible procomitial action (1,2). However, during its clinical evaluation, baclofen was noted to reduce spasticity. Numerous clinical-efficacy studies were conducted in the 1970s, and after that the interest became mostly oriented towards a comparison with the newly available tizanidine in the 1980s. At the same time, several studies addressed the mechanisms of action of baclofen, both at the cellular and spinal-tissue levels. In this chapter, we will first review the chemistry and cellular mechanisms of action, the physiologic effect at the spinal-cord level, and the pharmacokinetics of baclofen. We will thereafter consider the clinical effects on spastic patients, and summarize a systematic review of published studies of patients with a variety of neurological disorders since the drug became available in 1966. We will also describe the possible side and toxic effects of baclofen, and finally present a recommended schedule of administration in different patient populations. Intrathecal baclofen (ITB) is discussed in Chapter 15.


Multiple Sclerosis Spinal Cord Injury Amyotrophic Lateral Sclerosis Cerebral Palsy Intrathecal Baclofen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rush, J. M. and Gibberd, F. B. (1990) Baclofen-induced epilepsy. J. R. Soc. Med. 83, 115–116.PubMedGoogle Scholar
  2. 2.
    Zak, R., Solomon, G., Petito, F., and Labar, D. (1994) Baclofen-induced generalized nonconvulsive status epilepticus. Ann. Neurol. 36, 113–114.PubMedCrossRefGoogle Scholar
  3. 3.
    Rice, G. P. A. (1987) Pharmacotherapy of spasticity: some theoretical and practical considerations. Can. J. Neurol. Sci. 14, 510–512.Google Scholar
  4. 4.
    Bowery, N. (1989) GABA-B receptors and their significance in mammalian pharmacology. Trends Pharmacol. Sci. 10, 401–407.PubMedCrossRefGoogle Scholar
  5. 5.
    Dressnandt, J., Carola, A., and Conrad, B. (1995) Influence of baclofen upon the alpha-motoneuron in spasticity by means of F-wave analysis. Muscle Nerve 18, 103–107.PubMedCrossRefGoogle Scholar
  6. 6.
    Young, R. R. et al. (1997) Current issues in spasticity. Neurology 3, 261–275.CrossRefGoogle Scholar
  7. 7.
    Fromm, G. H. (1994) Baclofen as an adjuvant analgesic.. 1. Pain. Symptom. Manag. 9, 500–509.CrossRefGoogle Scholar
  8. 8.
    Davidoff, R. A. (1985) Antispasticity drugs: mechanisms of action. Neurology 17, 107–116.Google Scholar
  9. 9.
    Faigle, J. W., Keberle, H., and Degen, P. H. (1980) Chemistry and pharmacokinetics of baclofen, in Spasticity: Disordered Motor Control (Feldman, R. G., Young, R. R., and Koella, W. P., eds.), Yearbook Medical, Chicago, pp. 94–100.Google Scholar
  10. 10.
    Peterson, G. M., McLean, S., and Millingen, K. S. (1985) Food does not affect the bioavailability of baclofen. Med. J. Aust. 42, 689–690.Google Scholar
  11. 11.
    McEllan, D. L. (1977) Co-contraction and stretch reflexes in spasticity during treatment with baclofen. J. Neurol. Neurosurg. Psych. 40, 30–38.CrossRefGoogle Scholar
  12. 12.
    Brogden, R. N., Speight, T. M., and Avery, G. S. (1974) Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 8, 1–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Wuis, E. W., Dirks, M. J. M., Termond, E. F. S, Vree, T. B., and Van der Kleijn, E. (1989) Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur. J. Clin. Pharmacol. 37, 181–184.CrossRefGoogle Scholar
  14. 14.
    Terrence, C. F. and Fromm, G. H. (1981) Complications of baclofen withdrawal. Arch. Neurol. 38, 588–589.PubMedCrossRefGoogle Scholar
  15. 15.
    Mills, P. J. and Jackson, A. D. M. (1977) A controlled trial of baclofen in children with cerebral palsy. J Intl. Med Res. 5, 398–404.Google Scholar
  16. 16.
    Milanov, I. G. (1992) Mechanisms of baclofen action on spasticity. Acta Neurol. Scand. 85, 305–310.PubMedCrossRefGoogle Scholar
  17. 17.
    Knutsson, E., Lindblom, U., and Martensson, A. (1973) Differences in effects in gamma and alpha spasticity induced by the GABA derivative baclofen (Lioresal). Brain 96, 29–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Duncan, G. W., Shamani, B. T., and Young, R. R. (1976) An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology 26, 441.PubMedCrossRefGoogle Scholar
  19. 19.
    Feldman, R. G., Kelly-Hayes, M., Conomy, J. P., and Foley, M. G. (1978) Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study. Neurology 28, 1094–1098.CrossRefGoogle Scholar
  20. 20.
    Jones, R. F. and Lance, J. W. (1976) Baclofen in the long term management of spasticity. Med. J. Aust. 1, 654–656.PubMedGoogle Scholar
  21. 21.
    Young, R. R. (1987) Physiologic and pharmacologic approaches to spasticity. Neurol. Clin. 5, 529–539.PubMedGoogle Scholar
  22. 22.
    Young, R. R. and Delwaide, P. J. (1981) Drug therapy: spasticity (second of two parts). N. Engl. J. Med. 304 (2), 96–99.PubMedCrossRefGoogle Scholar
  23. 23.
    Hudgson, P. and Weightman, D. (1971) Baclofen in the treatment of spasticity. BMJ 4, 15–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Cartlidge, N. E. F., Hudgson, P., and Weightman, D. (1974) A comparison of baclofen and diazepam in the treatment of spasticity. J. Neurol. Sci. 23, 17–24.CrossRefGoogle Scholar
  25. 25.
    Cendrowski, W. and Sobczyk, W. (1977) Clonazepam, baclofen and placebo in the treatment of spasticity. Eur. Neurol. 16, 257–262.PubMedCrossRefGoogle Scholar
  26. 26.
    Roussan, C., Terrence, G., and Fromm, G. H. (1985) Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapy 4, 278–284.Google Scholar
  27. 27.
    Nance, P. W. (1994) A comparison of clonidine, cyproheptadine, and baclofen in spastic spinal cord injured patients. J. Am. Paraplegia Soc. 17, 150–156.PubMedGoogle Scholar
  28. 28.
    Norris, H., Sang, K., Sachais, B., and Carey, M. (1979) Trial of baclofen in arnyotrophic lateral sclerosis. Arch. Neurol. 36 715–716.PubMedCrossRefGoogle Scholar
  29. 29.
    From, A. and Heltberg, A. (1975) A double-blind trial with baclofen and diazepam in spasticity due to multiple sclerosis. Acta Neurol. Scand. 51, 158–166.PubMedCrossRefGoogle Scholar
  30. 30.
    Eysette, M., Rohmer, F., Serratrice, G., Warter, J. M., and Boisson, D. (1988) Multi-center, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr. Med. Res. Opin. 10, 699–708.CrossRefGoogle Scholar
  31. 31.
    Smolenski, C., Muff, S., and Smolenski-Kautz, S. (1981) A double-blind comparative trial of a new muscle relaxant, tizanidine, and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr. Med. Res. Opin. 7, 374–383.PubMedGoogle Scholar
  32. 32.
    Newman, P. M., Nogues, M., Newman, P. K., Weightman, D., and Hudgson, P. (1982) Tizanidine in the treatment of spasticity. Eur. J. Clin. Pharmacol. 23, 31–35.PubMedCrossRefGoogle Scholar
  33. 33.
    Stien, R., Nordal, H. J., Oftedal, S. I., and Slettebo, M. (1987) The treatment of spasticity in multiple sclerosis: a doubleblind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol. Scand. 75, 190–194.CrossRefGoogle Scholar
  34. 34.
    Bass, B., Weinshenker, B., Rice, G. P. A, Noseworthy, J. H., Cameron, M. G. P., Hader, W., Bouchard, S., and Ebers, G. C. (1988) Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can. J. Neurol. Sci. 15, 15–19.PubMedGoogle Scholar
  35. 35.
    Jamous, A., Kenedy, P., and Grey, N. (1994) Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia 32, 349–353.PubMedCrossRefGoogle Scholar
  36. 36.
    Hulme, A., MacLennan, W. J., Ritchie, R. T., John, V. A., and Shotton, P. A. (1985) Baclofen in the elderly stroke patient: its side effects and pharmacokinetics. Eur. J. Clin. Pharmacol. 29, 467–469.PubMedCrossRefGoogle Scholar
  37. 37.
    Smith, M. B., Bar, S. P., Nelson, L. M., and Franklin, G. M. (1992) Baclofen effect on quadriceps strength in multiple sclerosis. Arch. Phys. Med. Rehabil. 73, 237–240.PubMedGoogle Scholar
  38. 38.
    Liu, H., Tsai, S., Liu, T., and Chi, C. (1991) Baclofen-induced frontal lobe syndrome: case report. Paraplegia 29, 554–556.PubMedCrossRefGoogle Scholar
  39. 39.
    Sommer, B. R. and Petrides, G. (1992) Cases of baclofen-induced psychotic depression. I Clin. Psych. 53, 211–212.Google Scholar
  40. 40.
    Roy, C. W. and Wakefield, I. R. (1986) Baclofen pseudopsychosis: a case report. Paraplegia 24, 318–321.CrossRefGoogle Scholar
  41. 41.
    Merritt, J. L. (1981) Management of spasticity in spinal cord injury. Mayo Clin. Proc. 56 614–622.Google Scholar
  42. 42.
    Chui, L. K. and Pelot, D. (1984) Hepatic enzyme elevations associated with baclofen. Clin. Pharm. 3, 196–197.PubMedGoogle Scholar
  43. 43.
    Aisen, M. L., Dietz, M., McDowell, F., and Kutt, H. (1994) Baclofen toxicity in a patient with subclinical renal insufficiency. Arch. Phys. Med. Rehabil. 75, 109–111.PubMedGoogle Scholar
  44. 44.
    Nugent, S., Katz, M. D., and Little, T. E. (1986) Baclofen overdose with cardiac conduction abnormalities: case report and review of the literature. Clin. Toxicol. 24 (4), 321–328.CrossRefGoogle Scholar
  45. Cumming, R. (1972) Multiple sclerosis in the Shetlands, with an evaluation of Lioresal. Postgrad. Med. J. Oct. (Suppl.) 34–37.Google Scholar
  46. 46.
    Harrison, S. A. and Wood, C. A. (1985) Hallucinations after preoperative baclofen discontinuation in spinal cord injury patients. Drug. Intell. Clin. Pharmacol. 19, 747–749.Google Scholar
  47. 47.
    Mandac, B. R., Hurvitz, E. A., and Nelson, V. S. (1993) Hyperthermia asso-Google Scholar
  48. ciated with baclofen withdrawal and increased spasticity. Arch. Phys. Med. Rehabil. 74 96–97.Google Scholar
  49. 48.
    Rivas, D. A., Chancellor, M. B., Hill, K., and Freedman, M. K. (1993) Neurological manifestations of baclofen withdrawal. J. Urol. 150, 1903–1905.PubMedGoogle Scholar
  50. 49.
    Garabedian-Ruffalo, S. M. and Ruffalo, R. (1985) Adverse effects secondary to baclofen withdrawal. Drug Intell. Clin. Pharm. 19, 304–306.PubMedGoogle Scholar
  51. 50.
    Sachais, B. A., Logue, J. N., and Carey, M. S. (1977) Baclofen, A new anti-spastic drug. Arch. Neurol. 34, 422–428.PubMedCrossRefGoogle Scholar
  52. 51.
    Smith, C. R., LaRocca, N. G., Giesser, B. S., and Scheinberg, L. C. (1991) High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 41, 1829–1831.CrossRefGoogle Scholar
  53. 52.
    Pinto, O. S., Polikar, M., and Debono, G. (1972) Results of international clinical trials with Lioresal. Postgrad. Med. J. Oct. (Suppl.) 18–23.Google Scholar
  54. 53.
    Albright, A. L. (1996) Baclofen in the treatment of cerebral palsy. I Child Neurol. 11, 77–83.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Eric P. Bastings
  • Amelito Malapira

There are no affiliations available

Personalised recommendations